BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hematopoietic cell
,
Ciprofibrate
,
rs6983267
,
VEGFA
,
nitric oxide metabolic process
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
t 18
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
GSK cancer cell line transcript profiling
Natural killer (NK) cells of Type 1 diabetes mice after T regulatory (Treg) cell depletion
T-cells from SLE patients and healthy donors with or without stimulation with nitric oxide and TCR.
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T …
A Novel de novo Balanced Reciprocal Translocation t(18;22) Associated with Recurrent Miscarriages: A…
T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell…
Association of IL-8 gene promoter -251 A/T and IL-18 gene promoter -137 G/C polymorphisms with head …
22q11.2 syndrome due to maternal translocation t(18;22) (pl1.2;q11.2).
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CA…
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advan…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ